INOVIO PHARMACEUTICALS, INC. annual report, FY2021

INOVIO Pharmaceuticals, Inc. — FY2021 Form 10-K

Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter filing. INOVIO is a clinical-stage biotechnology company developing DNA vaccines, immunotherapies, and DNA-encoded antibodies using its SynCon and CELLECTRA platforms. No product candidates were approved for sale, and the company reported no product-sales revenue.

Financial performance and liquidity

Metric	FY2021	FY2020
Total revenue	$1.8 million	$7.4 million
Research and development expense	$249.2 million	$94.2 million
General and administrative expense	$53.8 million	$37.2 million
Operating loss	$301.2 million	$124.1 million
Net loss attributable to INOVIO	$303.7 million	$166.4 million
Basic and diluted loss per share	$1.45	$1.07
Net cash used in operating activities	$215.7 million	$178.0 million

Revenue fell 76%, mainly because 2020 included Advaccine upfront and milestone revenue and a Plumbline milestone that did not recur. Operating expenses rose 130%, led by INO-4800 development and manufacturing activities. The company recorded $53.7 million of grant contributions as reductions to R&D expense; grants are not included in reported revenue. Product margins are not meaningful because the company had no product sales. The $755,000 of DoD device revenue was recognized at a 100% margin because the related inventory had previously been written down to zero.

At year-end, cash and cash equivalents were $71.1 million and short-term investments were $330.2 million, totaling $401.3 million, versus $411.6 million a year earlier. Working capital was $382.7 million, down from $429.5 million. Operating cash use increased year over year; investing cash use was $175.3 million and financing cash provided was $211.5 million. Management stated that available cash and short-term investments were sufficient for planned working-capital needs for at least 12 months from the report date, while also stating that additional capital will be needed to fund future development.

Debt included $15.0 million carrying value of 6.5% convertible senior notes due 2024. Contractual payments, including interest, totaled $19.1 million. The December 2019 convertible bonds were converted into shares in March 2021. INOVIO raised $162.1 million net in a January 2021 public offering and $47.7 million net through its ATM program during 2021; the new ATM program had $251.6 million of capacity remaining at year-end. Common shares outstanding increased to 217.4 million from 186.9 million.

Programs, changes, and outlook

• VGX-3100, cervical HSIL: REVEAL1 met the primary endpoint in the evaluable mITT population (23.7% versus 11.3%; p=0.022), but not in the protocol-defined ITT population (22.5% versus 11.1%; not statistically significant). The confirmatory REVEAL2 trial completed enrollment in Q4 2021; topline data were expected in the second half of 2022. The distinction between populations is material to interpreting the result.
• INO-4800, COVID-19: The global Phase 3 INNOVATE trial paused new enrollment following a Data Safety Monitoring Board recommendation and amid the Omicron variant. INOVIO planned to seek approval to change the primary endpoint from prevention of symptomatic disease to prevention of severe disease. Interim efficacy data were no longer expected in the first half of 2022. The filing describes preserved T-cell responses but substantially reduced binding and neutralizing antibodies against Omicron, based on in-vitro assessment.
• Other pipeline: Enrollment was completed in the first 32-participant INO-3107 Phase 1/2 cohort for recurrent respiratory papillomatosis; preliminary efficacy data were expected in the second half of 2022. INO-4700 MERS and INO-4500 Lassa programs continued with CEPI support. The INO-5401 GBM program reported 24-month overall survival of 22% in the MGMT-unmethylated cohort and 55% in the methylated cohort; management cautioned that the data may suggest benefit, but they do not establish efficacy.
• Funding and collaboration changes: The DoD discontinued funding for the U.S. Phase 3 segment of INNOVATE in April 2021, while continuing other support under its device-development agreement and device procurement contract. AstraZeneca terminated its MEDI0457/INO-3112 collaboration in October 2021. Advaccine’s INO-4800 agreement provides for up to $206 million in potential milestones and high-single-digit royalties, contingent on development, approval, and sales.

Risks, contingencies, and unusual items

• INOVIO has an accumulated deficit of $1.2 billion, expects continued substantial losses, and may never achieve profitability. Future funding could require equity issuance, dilution, debt, licensing, or reduced or delayed programs.
• Development, regulatory, manufacturing, and commercialization outcomes remain uncertain. INOVIO relies on contract manufacturers, has disclosed supply constraints and prior manufacturing-capacity issues, and had $47.4 million of minimum INO-4800 manufacturing purchases committed for 2022.
• Three principal litigation matters remained unresolved: securities and derivative shareholder actions relating to COVID-19 disclosures, litigation with VGXI over a supply agreement, and litigation with GeneOne concerning a CELLECTRA device license agreement. The filing does not provide a clear estimate of potential loss.
• Revenue was concentrated: the DoD represented 43% and affiliated entity Plumbline 14% of 2021 revenue. The company also disclosed substantial customer concentration in accounts receivable.
• FY2021 R&D expense included $35.0 million related to manufacturing-capacity access fees; the company also cited $21.9 million for acquisition and installation of INO-4800 manufacturing equipment. The filing’s accounting presentation should be reviewed when assessing recurring R&D costs and cash requirements.
• The auditor issued an unqualified opinion on the financial statements and on internal control over financial reporting. The audit identified accrued clinical-trial expenses as a critical audit matter, noting the estimates depend on detailed information from clinical personnel and third-party providers.

Most important facts for investors to verify

1. REVEAL1’s ITT versus mITT efficacy results, the statistical significance and clinical relevance, and the confirmatory REVEAL2 outcome.
2. INNOVATE’s regulatory path after the enrollment pause, whether the endpoint amendment is accepted, and the trial’s revised timeline and funding.
3. Cash burn, the pace of investment maturities and spending, committed manufacturing payments, and whether management’s stated 12-month liquidity outlook remains adequate.
4. Availability and terms of additional financing, including use of the remaining ATM capacity and resulting potential dilution.
5. Developments in the shareholder and supplier litigation, manufacturing capacity and supply reliability, and continued funding or performance by government and commercial partners.